Global HER-2 Targeted Drugs for Breast Cancer Market Insights and Forecast to 2028

  • Report ID:229581
  • Industry Name: Medical Care
  • Publishing Date: Jun-22
  • No. of Pages: 108
                              
HER-2 Targeted Drugs for Breast Cancer market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global HER-2 Targeted Drugs for Breast Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type Trastuzumab Pertuzumab Lapatinib Neratinib Trastuzumab Emtansine Pyrotinib Other Segment by Application Hospital Clinic Drug Center Other By Company Roche Chugai Pharmaceutical GlaxoSmithKline Novartis Pfizer CANbridge Puma Biotechnology Hengrui Medicine Beacon Pharmaceuticals Limited Hetero DrugsĀ  By Region North America United States Canada Europe Germany France UK Italy Russia Nordic Countries Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA
                        
1 Report Business Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 Trastuzumab 1.2.3 Pertuzumab 1.2.4 Lapatinib 1.2.5 Neratinib 1.2.6 Trastuzumab Emtansine 1.2.7 Pyrotinib 1.2.8 Other 1.3 Market by Application 1.3.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Drug Center 1.3.5 Other 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global HER-2 Targeted Drugs for Breast Cancer Market Perspective (2017-2028) 2.2 HER-2 Targeted Drugs for Breast Cancer Growth Trends by Region 2.2.1 HER-2 Targeted Drugs for Breast Cancer Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 HER-2 Targeted Drugs for Breast Cancer Historic Market Size by Region (2017-2022) 2.2.3 HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Region (2023-2028) 2.3 HER-2 Targeted Drugs for Breast Cancer Market Dynamics 2.3.1 HER-2 Targeted Drugs for Breast Cancer Industry Trends 2.3.2 HER-2 Targeted Drugs for Breast Cancer Market Drivers 2.3.3 HER-2 Targeted Drugs for Breast Cancer Market Challenges 2.3.4 HER-2 Targeted Drugs for Breast Cancer Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top HER-2 Targeted Drugs for Breast Cancer Players by Revenue 3.1.1 Global Top HER-2 Targeted Drugs for Breast Cancer Players by Revenue (2017-2022) 3.1.2 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Players (2017-2022) 3.2 Global HER-2 Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by HER-2 Targeted Drugs for Breast Cancer Revenue 3.4 Global HER-2 Targeted Drugs for Breast Cancer Market Concentration Ratio 3.4.1 Global HER-2 Targeted Drugs for Breast Cancer Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by HER-2 Targeted Drugs for Breast Cancer Revenue in 2021 3.5 HER-2 Targeted Drugs for Breast Cancer Key Players Head office and Area Served 3.6 Key Players HER-2 Targeted Drugs for Breast Cancer Product Solution and Service 3.7 Date of Enter into HER-2 Targeted Drugs for Breast Cancer Market 3.8 Mergers & Acquisitions, Expansion Plans 4 HER-2 Targeted Drugs for Breast Cancer Breakdown Data by Type 4.1 Global HER-2 Targeted Drugs for Breast Cancer Historic Market Size by Type (2017-2022) 4.2 Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2023-2028) 5 HER-2 Targeted Drugs for Breast Cancer Breakdown Data by Application 5.1 Global HER-2 Targeted Drugs for Breast Cancer Historic Market Size by Application (2017-2022) 5.2 Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America HER-2 Targeted Drugs for Breast Cancer Market Size (2017-2028) 6.2 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Type 6.2.1 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2017-2022) 6.2.2 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2023-2028) 6.2.3 North America HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2017-2028) 6.3 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Application 6.3.1 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2017-2022) 6.3.2 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2023-2028) 6.3.3 North America HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2017-2028) 6.4 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Country 6.4.1 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2017-2022) 6.4.2 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2023-2028) 6.4.3 U.S. 6.4.4 Canada 7 Europe 7.1 Europe HER-2 Targeted Drugs for Breast Cancer Market Size (2017-2028) 7.2 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Type 7.2.1 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2017-2022) 7.2.2 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2023-2028) 7.2.3 Europe HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2017-2028) 7.3 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Application 7.3.1 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2017-2022) 7.3.2 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2023-2028) 7.3.3 Europe HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2017-2028) 7.4 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Country 7.4.1 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2017-2022) 7.4.2 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2023-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size (2017-2028) 8.2 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Type 8.2.1 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2017-2022) 8.2.2 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2023-2028) 8.2.3 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2017-2028) 8.3 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Application 8.3.1 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2017-2022) 8.3.2 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2023-2028) 8.3.3 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2017-2028) 8.4 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Region 8.4.1 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Region (2017-2022) 8.4.2 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Region (2023-2028) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size (2017-2028) 9.2 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Type 9.2.1 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2017-2022) 9.2.2 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2023-2028) 9.2.3 Latin America HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2017-2028) 9.3 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Application 9.3.1 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2017-2022) 9.3.2 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2023-2028) 9.3.3 Latin America HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2017-2028) 9.4 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Country 9.4.1 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2017-2022) 9.4.2 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2023-2028) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size (2017-2028) 10.2 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Type 10.2.1 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2017-2022) 10.2.2 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2023-2028) 10.2.3 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2017-2028) 10.3 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Application 10.3.1 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2017-2022) 10.3.2 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2023-2028) 10.3.3 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2017-2028) 10.4 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Country 10.4.1 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2017-2022) 10.4.2 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2023-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Roche 11.1.1 Roche Company Details 11.1.2 Roche Business Overview 11.1.3 Roche HER-2 Targeted Drugs for Breast Cancer Introduction 11.1.4 Roche Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) 11.1.5 Roche Recent Developments 11.2 Chugai Pharmaceutical 11.2.1 Chugai Pharmaceutical Company Details 11.2.2 Chugai Pharmaceutical Business Overview 11.2.3 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Introduction 11.2.4 Chugai Pharmaceutical Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) 11.2.5 Chugai Pharmaceutical Recent Developments 11.3 GlaxoSmithKline 11.3.1 GlaxoSmithKline Company Details 11.3.2 GlaxoSmithKline Business Overview 11.3.3 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Introduction 11.3.4 GlaxoSmithKline Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) 11.3.5 GlaxoSmithKline Recent Developments 11.4 Novartis 11.4.1 Novartis Company Details 11.4.2 Novartis Business Overview 11.4.3 Novartis HER-2 Targeted Drugs for Breast Cancer Introduction 11.4.4 Novartis Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) 11.4.5 Novartis Recent Developments 11.5 Pfizer 11.5.1 Pfizer Company Details 11.5.2 Pfizer Business Overview 11.5.3 Pfizer HER-2 Targeted Drugs for Breast Cancer Introduction 11.5.4 Pfizer Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) 11.5.5 Pfizer Recent Developments 11.6 CANbridge 11.6.1 CANbridge Company Details 11.6.2 CANbridge Business Overview 11.6.3 CANbridge HER-2 Targeted Drugs for Breast Cancer Introduction 11.6.4 CANbridge Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) 11.6.5 CANbridge Recent Developments 11.7 Puma Biotechnology 11.7.1 Puma Biotechnology Company Details 11.7.2 Puma Biotechnology Business Overview 11.7.3 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Introduction 11.7.4 Puma Biotechnology Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) 11.7.5 Puma Biotechnology Recent Developments 11.8 Hengrui Medicine 11.8.1 Hengrui Medicine Company Details 11.8.2 Hengrui Medicine Business Overview 11.8.3 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Introduction 11.8.4 Hengrui Medicine Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) 11.8.5 Hengrui Medicine Recent Developments 11.9 Beacon Pharmaceuticals Limited 11.9.1 Beacon Pharmaceuticals Limited Company Details 11.9.2 Beacon Pharmaceuticals Limited Business Overview 11.9.3 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Introduction 11.9.4 Beacon Pharmaceuticals Limited Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) 11.9.5 Beacon Pharmaceuticals Limited Recent Developments 11.10 Hetero DrugsĀ  11.10.1 Hetero DrugsĀ  Company Details 11.10.2 Hetero DrugsĀ  Business Overview 11.10.3 Hetero DrugsĀ  HER-2 Targeted Drugs for Breast Cancer Introduction 11.10.4 Hetero DrugsĀ  Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) 11.10.5 Hetero DrugsĀ  Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Author Details 13.3 Disclaimer
                
List of Tables Table 1. Global HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028 Table 2. Key Players of Trastuzumab Table 3. Key Players of Pertuzumab Table 4. Key Players of Lapatinib Table 5. Key Players of Neratinib Table 6. Key Players of Trastuzumab Emtansine Table 7. Key Players of Pyrotinib Table 8. Key Players of Other Table 9. Global HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028 Table 10. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 11. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Region (2017-2022) & (US$ Million) Table 12. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Region (2017-2022) Table 13. Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 14. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Region (2023-2028) Table 15. HER-2 Targeted Drugs for Breast Cancer Market Trends Table 16. HER-2 Targeted Drugs for Breast Cancer Market Drivers Table 17. HER-2 Targeted Drugs for Breast Cancer Market Challenges Table 18. HER-2 Targeted Drugs for Breast Cancer Market Restraints Table 19. Global HER-2 Targeted Drugs for Breast Cancer Revenue by Players (2017-2022) & (US$ Million) Table 20. Global HER-2 Targeted Drugs for Breast Cancer Revenue Share by Players (2017-2022) Table 21. Global Top HER-2 Targeted Drugs for Breast Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HER-2 Targeted Drugs for Breast Cancer as of 2021) Table 22. Ranking of Global Top HER-2 Targeted Drugs for Breast Cancer Companies by Revenue (US$ Million) in 2021 Table 23. Global 5 Largest Players Market Share by HER-2 Targeted Drugs for Breast Cancer Revenue (CR5 and HHI) & (2017-2022) Table 24. Key Players Headquarters and Area Served Table 25. Key Players HER-2 Targeted Drugs for Breast Cancer Product Solution and Service Table 26. Date of Enter into HER-2 Targeted Drugs for Breast Cancer Market Table 27. Mergers & Acquisitions, Expansion Plans Table 28. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2017-2022) & (US$ Million) Table 29. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Type (2017-2022) Table 30. Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 31. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Type (2023-2028) Table 32. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2017-2022) & (US$ Million) Table 33. Global HER-2 Targeted Drugs for Breast Cancer Revenue Share by Application (2017-2022) Table 34. Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 35. Global HER-2 Targeted Drugs for Breast Cancer Revenue Share by Application (2023-2028) Table 36. North America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2017-2022) & (US$ Million) Table 37. North America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2023-2028) & (US$ Million) Table 38. North America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2017-2022) & (US$ Million) Table 39. North America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2023-2028) & (US$ Million) Table 40. North America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2017-2022) & (US$ Million) Table 41. North America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2023-2028) & (US$ Million) Table 42. Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2017-2022) & (US$ Million) Table 43. Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2023-2028) & (US$ Million) Table 44. Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2017-2022) & (US$ Million) Table 45. Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2023-2028) & (US$ Million) Table 46. Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2017-2022) & (US$ Million) Table 47. Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2023-2028) & (US$ Million) Table 48. Asia Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2017-2022) & (US$ Million) Table 49. Asia Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2023-2028) & (US$ Million) Table 50. Asia Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2017-2022) & (US$ Million) Table 51. Asia Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2023-2028) & (US$ Million) Table 52. Asia Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Region (2017-2022) & (US$ Million) Table 53. Asia Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Region (2023-2028) & (US$ Million) Table 54. Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2017-2022) & (US$ Million) Table 55. Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2023-2028) & (US$ Million) Table 56. Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2017-2022) & (US$ Million) Table 57. Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2023-2028) & (US$ Million) Table 58. Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2017-2022) & (US$ Million) Table 59. Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2023-2028) & (US$ Million) Table 60. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2017-2022) & (US$ Million) Table 61. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2023-2028) & (US$ Million) Table 62. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2017-2022) & (US$ Million) Table 63. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2023-2028) & (US$ Million) Table 64. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2017-2022) & (US$ Million) Table 65. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2023-2028) & (US$ Million) Table 66. Roche Company Details Table 67. Roche Business Overview Table 68. Roche HER-2 Targeted Drugs for Breast Cancer Product Table 69. Roche Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) & (US$ Million) Table 70. Roche Recent Developments Table 71. Chugai Pharmaceutical Company Details Table 72. Chugai Pharmaceutical Business Overview Table 73. Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Product Table 74. Chugai Pharmaceutical Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) & (US$ Million) Table 75. Chugai Pharmaceutical Recent Developments Table 76. GlaxoSmithKline Company Details Table 77. GlaxoSmithKline Business Overview Table 78. GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Product Table 79. GlaxoSmithKline Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) & (US$ Million) Table 80. GlaxoSmithKline Recent Developments Table 81. Novartis Company Details Table 82. Novartis Business Overview Table 83. Novartis HER-2 Targeted Drugs for Breast Cancer Product Table 84. Novartis Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) & (US$ Million) Table 85. Novartis Recent Developments Table 86. Pfizer Company Details Table 87. Pfizer Business Overview Table 88. Pfizer HER-2 Targeted Drugs for Breast Cancer Product Table 89. Pfizer Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) & (US$ Million) Table 90. Pfizer Recent Developments Table 91. CANbridge Company Details Table 92. CANbridge Business Overview Table 93. CANbridge HER-2 Targeted Drugs for Breast Cancer Product Table 94. CANbridge Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) & (US$ Million) Table 95. CANbridge Recent Developments Table 96. Puma Biotechnology Company Details Table 97. Puma Biotechnology Business Overview Table 98. Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Product Table 99. Puma Biotechnology Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) & (US$ Million) Table 100. Puma Biotechnology Recent Developments Table 101. Hengrui Medicine Company Details Table 102. Hengrui Medicine Business Overview Table 103. Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Product Table 104. Hengrui Medicine Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) & (US$ Million) Table 105. Hengrui Medicine Recent Developments Table 106. Beacon Pharmaceuticals Limited Company Details Table 107. Beacon Pharmaceuticals Limited Business Overview Table 108. Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Product Table 109. Beacon Pharmaceuticals Limited Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) & (US$ Million) Table 110. Beacon Pharmaceuticals Limited Recent Developments Table 111. Hetero DrugsĀ  Company Details Table 112. Hetero DrugsĀ  Business Overview Table 113. Hetero DrugsĀ  HER-2 Targeted Drugs for Breast Cancer Product Table 114. Hetero DrugsĀ  Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) & (US$ Million) Table 115. Hetero DrugsĀ  Recent Developments Table 116. Research Programs/Design for This Report Table 117. Key Data Information from Secondary Sources Table 118. Key Data Information from Primary Sources List of Figures Figure 1. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Type: 2021 VS 2028 Figure 2. Trastuzumab Features Figure 3. Pertuzumab Features Figure 4. Lapatinib Features Figure 5. Neratinib Features Figure 6. Trastuzumab Emtansine Features Figure 7. Pyrotinib Features Figure 8. Other Features Figure 9. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Application: 2021 VS 2028 Figure 10. Hospital Case Studies Figure 11. Clinic Case Studies Figure 12. Drug Center Case Studies Figure 13. Other Case Studies Figure 14. HER-2 Targeted Drugs for Breast Cancer Report Years Considered Figure 15. Global HER-2 Targeted Drugs for Breast Cancer Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 16. Global HER-2 Targeted Drugs for Breast Cancer Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 17. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Region: 2021 VS 2028 Figure 18. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Players in 2021 Figure 19. Global Top HER-2 Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HER-2 Targeted Drugs for Breast Cancer as of 2021) Figure 20. The Top 10 and 5 Players Market Share by HER-2 Targeted Drugs for Breast Cancer Revenue in 2021 Figure 21. North America HER-2 Targeted Drugs for Breast Cancer Market Size YoY (2017-2028) & (US$ Million) Figure 22. North America HER-2 Targeted Drugs for Breast Cancer Market Size Market Share by Type (2017-2028) Figure 23. North America HER-2 Targeted Drugs for Breast Cancer Market Size Market Share by Application (2017-2028) Figure 24. North America HER-2 Targeted Drugs for Breast Cancer Market Size Share by Country (2017-2028) Figure 25. United States HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 26. Canada HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. Europe HER-2 Targeted Drugs for Breast Cancer Market Size YoY (2017-2028) & (US$ Million) Figure 28. Europe HER-2 Targeted Drugs for Breast Cancer Market Size Market Share by Type (2017-2028) Figure 29. Europe HER-2 Targeted Drugs for Breast Cancer Market Size Market Share by Application (2017-2028) Figure 30. Europe HER-2 Targeted Drugs for Breast Cancer Market Size Share by Country (2017-2028) Figure 31. Germany HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. France HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. U.K. HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. Italy HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. Russia HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. Nordic Countries HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size YoY (2017-2028) & (US$ Million) Figure 38. Asia Pacific HER-2 Targeted Drugs for Breast Cancer Market Size Market Share by Type (2017-2028) Figure 39. Asia Pacific HER-2 Targeted Drugs for Breast Cancer Market Size Market Share by Application (2017-2028) Figure 40. Asia Pacific HER-2 Targeted Drugs for Breast Cancer Market Size Share by Region (2017-2028) Figure 41. China HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Japan HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. South Korea HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 44. Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 45. India HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 46. Australia HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) List of Figures Figure 47. Latin America HER-2 Targeted Drugs for Breast Cancer Market Size YoY (2017-2028) & (US$ Million) Figure 48. Latin America HER-2 Targeted Drugs for Breast Cancer Market Size Market Share by Type (2017-2028) Figure 49. Latin America HER-2 Targeted Drugs for Breast Cancer Market Size Market Share by Application (2017-2028) Figure 50. Latin America HER-2 Targeted Drugs for Breast Cancer Market Size Share by Country (2017-2028) Figure 51. Mexico HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 52. Brazil HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 53. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size YoY (2017-2028) & (US$ Million) Figure 54. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Market Size Market Share by Type (2017-2028) Figure 55. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Market Size Market Share by Application (2017-2028) Figure 56. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Market Size Share by Country (2017-2028) Figure 57. Turkey HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 58. Saudi Arabia HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 59. UAE HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 60. Roche Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) Figure 61. Chugai Pharmaceutical Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) Figure 62. GlaxoSmithKline Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) Figure 63. Novartis Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) Figure 64. Pfizer Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) Figure 65. CANbridge Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) Figure 66. Puma Biotechnology Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) Figure 67. Hengrui Medicine Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) Figure 68. Beacon Pharmaceuticals Limited Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) Figure 69. Hetero DrugsĀ  Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2017-2022) Figure 70. Bottom-up and Top-down Approaches for This Report Figure 71. Data Triangulation Figure 72. Key Executives Interviewed

Purchase Report

Single User 3480
Multi User 5250
Corporate User 6960
Buy

Purchase Report

Customize the purchase as per your specific research needs:

  • 20% additional customization
  • Request for country level reports
  • Request for historical statistics
  • Additional company profile on request

Why Choose Our Report?

24/5 Research support

Get your queries resolved from an industry expert

Custom research service

Design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.